Last updated: February 19, 2026
Secukinumab, a fully human monoclonal antibody targeting interleukin-17A (IL-17A), holds a significant position in the treatment of inflammatory diseases. Its market performance is driven by efficacy in psoriasis, psoriatic arthritis, ankylosing spondylitis, and other related conditions. Financial projections indicate continued growth, influenced by patent exclusivity, market penetration, and competitive landscape.
What is the Current Market Status of Secukinumab?
Secukinumab, marketed by Novartis as Cosentyx, has achieved blockbuster status. The drug targets the IL-17A cytokine, a key mediator of inflammation in several autoimmune diseases. Its approval across multiple indications has broadened its patient base and revenue generation.
Key Indications and Regulatory Approvals:
- Plaque Psoriasis: Approved in the U.S. in January 2015 and in Europe in January 2015.
- Psoriatic Arthritis: Approved in the U.S. in January 2016 and in Europe in September 2015.
- Ankylosing Spondylitis: Approved in the U.S. in October 2015 and in Europe in October 2015.
- Non-radiographic Axial Spondyloarthritis: Approved in the U.S. in December 2019 and in Europe in June 2019.
- Pediatric Plaque Psoriasis: Approved in the U.S. in May 2019 and in Europe in October 2019.
The drug's success is attributable to its demonstrated efficacy, favorable safety profile compared to some older biologic agents, and convenient dosing regimens, including a pre-filled syringe and pen.
Global Sales Performance:
Novartis reported net sales for Cosentyx:
- 2022: USD 4.7 billion
- 2021: USD 4.7 billion
- 2020: USD 4.0 billion
These figures highlight consistent year-over-year revenue, with substantial growth observed from 2020 to 2021.
What are the Key Drivers of Secukinumab's Market Growth?
Secukinumab's market expansion is fueled by several factors, including its broad therapeutic application, increasing diagnosis rates of autoimmune diseases, and a robust clinical data package supporting its use.
Therapeutic Breadth and Clinical Efficacy:
The drug's ability to treat multiple chronic inflammatory conditions provides a significant commercial advantage. Clinical trials have consistently shown secukinumab's superiority in achieving and maintaining disease remission compared to placebo and, in some cases, comparator biologic agents. For example, the PURE study demonstrated high rates of skin clearance in moderate to severe plaque psoriasis. (1)
Patient Population Growth and Diagnosis Rates:
The global prevalence of psoriasis, psoriatic arthritis, and ankylosing spondylitis is increasing. Factors contributing to this include improved diagnostic capabilities, greater patient awareness, and an aging population. As a result, the pool of eligible patients for advanced biologic therapies like secukinumab expands.
Geographic Market Expansion:
Novartis has secured approvals and market access for Cosentyx in major pharmaceutical markets, including North America, Europe, and Asia. Ongoing efforts focus on expanding access in emerging markets, which represent significant untapped potential.
Sustained Innovation and Lifecycle Management:
Novartis actively invests in further research and development for secukinumab. This includes exploring new indications, optimizing dosing regimens, and developing patient-centric delivery systems to maintain its competitive edge and extend its market lifecycle.
What is the Competitive Landscape for Secukinumab?
Secukinumab operates in a highly competitive biologics market. Its primary competitors are other IL-17 inhibitors, TNF-alpha inhibitors, and IL-23 inhibitors, each with varying efficacy, safety profiles, and market positioning.
Key Competitors and Their Mechanisms of Action:
- IL-17 Inhibitors:
- Ixekizumab (Taltz, Eli Lilly): Targets IL-17A, IL-17F, and IL-17AF. Approved for psoriasis, psoriatic arthritis, and ankylosing spondylitis.
- Bimekizumab (Bimzelx, UCB): Dual inhibitor of IL-17A and IL-17F. Approved for psoriasis and psoriatic arthritis.
- TNF-alpha Inhibitors:
- Adalimumab (Humira, AbbVie): A widely prescribed TNF-alpha inhibitor with broad indications for inflammatory diseases.
- Etanercept (Enbrel, Amgen/Pfizer): Another established TNF-alpha inhibitor.
- Infliximab (Remicade, Janssen): A chimeric monoclonal antibody targeting TNF-alpha.
- IL-23 Inhibitors:
- Guselkumab (Tremfya, Janssen): Targets IL-23. Approved for psoriasis and psoriatic arthritis.
- Tildrakizumab (Ilumya, Sun Pharma): Targets IL-23. Approved for psoriasis.
- Risankizumab (Skyrizi, AbbVie): Targets IL-23. Approved for psoriasis, psoriatic arthritis, and Crohn's disease.
Comparative Efficacy and Safety:
Direct head-to-head trials are crucial for differentiating secukinumab. While secukinumab has demonstrated strong efficacy, newer agents like bimekizumab and risankizumab are showing competitive or superior outcomes in specific patient subgroups and indications. (2, 3) Safety profiles are generally favorable across this class, but subtle differences in adverse event rates can influence physician prescribing habits.
Market Share Dynamics:
The market for IL-17 inhibitors is growing rapidly. Secukinumab has maintained a significant market share, but faces increasing pressure from newer entrants with potentially enhanced efficacy or novel mechanisms. The biosimilar landscape for older biologics like adalimumab also indirectly impacts the market by increasing treatment options and potentially lowering overall treatment costs.
What is the Patent Landscape and Exclusivity Status of Secukinumab?
The patent protection for secukinumab is a critical determinant of its future revenue stream. Novartis holds key patents covering the compound, its use, and manufacturing processes.
Key Patent Expirations:
- U.S. Compound Patents: The primary U.S. compound patents for secukinumab have expired or are nearing expiration. For instance, U.S. Patent No. 8,158,157, covering antibody compositions, is a key patent.
- European Patent Expirations: Similar patent expiries are observed in major European markets.
- Data Exclusivity: In addition to patent protection, regulatory data exclusivity periods provide a buffer against generic competition. These periods vary by jurisdiction.
Impact of Biosimilar Entry:
The expiration of core patents opens the door for biosimilar manufacturers. While the development and approval of biosimilars are complex and time-consuming, their eventual market entry can significantly erode the market share and pricing power of the originator biologic. Companies are actively seeking to develop secukinumab biosimilars.
Novartis's Patent Strategy:
Novartis employs strategies to defend its intellectual property, including pursuing method-of-use patents for new indications or optimized treatment regimens. These secondary patents can extend market exclusivity in specific applications. However, the fundamental protection on the active compound is paramount.
Projected Biosimilar Impact:
Industry analysts anticipate the emergence of secukinumab biosimilars in the U.S. and Europe within the next three to five years. The first biosimilar entries are expected to exert downward pressure on pricing, leading to a gradual decline in secukinumab's revenue from its peak.
What is the Financial Trajectory and Revenue Outlook for Secukinumab?
Secukinumab's financial trajectory is projected to remain strong in the near to medium term, with a gradual decline anticipated post-biosimilar entry.
Revenue Growth Projections:
- 2023-2025: Continued modest growth driven by new indications, market penetration in emerging markets, and physician adoption. Analysts project annual sales to reach USD 6 billion or higher during this period. (4)
- 2026 onwards: Anticipated decline in revenue as biosimilars enter the market. The rate of decline will depend on the number of biosimilar competitors, their pricing strategies, and the uptake of biosimilars by healthcare providers and payers.
Factors Influencing Future Revenue:
- Label Expansions: Approval for additional indications (e.g., other inflammatory bowel diseases) could bolster revenue.
- Pricing Pressures: Increased competition from biosimilars and ongoing payer negotiations for drug reimbursement will impact pricing.
- Geographic Penetration: Success in expanding access and adoption in high-growth emerging markets is crucial for mitigating biosimilar-induced revenue erosion.
- Real-World Evidence: Generation of robust real-world evidence supporting long-term safety and effectiveness can reinforce physician confidence and patient adherence.
Novartis's Strategic Responses:
Novartis is likely to focus on maximizing Cosentyx's value through lifecycle management, leveraging its broader immunology portfolio, and potentially exploring partnerships or divestitures as patent cliffs approach.
Key Takeaways
- Secukinumab (Cosentyx) is a leading biologic for inflammatory diseases, achieving blockbuster status with USD 4.7 billion in net sales in 2022.
- Market growth is driven by its broad therapeutic applications, increasing diagnosis rates of autoimmune diseases, and robust clinical data.
- The competitive landscape is intense, featuring other IL-17, TNF-alpha, and IL-23 inhibitors, with emerging agents showing high efficacy.
- Key U.S. and European compound patents are expiring, paving the way for biosimilar entry within the next three to five years.
- Revenue is projected to grow modestly through 2025, followed by a decline upon the introduction of biosimilars.
Frequently Asked Questions
What are the primary indications for which secukinumab is approved?
Secukinumab is approved for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis, as well as pediatric plaque psoriasis.
When are the key patent expiries for secukinumab expected in major markets?
While specific patent expiry dates vary, the core compound patents for secukinumab in the U.S. and Europe are expiring in the near term, leading to anticipated biosimilar entry within the next three to five years.
What is the expected financial impact of biosimilar entry on secukinumab's revenue?
Biosimilar entry is projected to exert downward pressure on pricing and lead to a decline in secukinumab's revenue from its peak, although the exact rate of decline will depend on market dynamics.
Which therapeutic classes represent the main competition for secukinumab?
The main competitors for secukinumab include other IL-17 inhibitors, TNF-alpha inhibitors, and IL-23 inhibitors.
What strategies is Novartis likely employing to maintain revenue for secukinumab in the face of patent expirations?
Novartis is likely to focus on lifecycle management, exploring new indications or optimized treatment regimens, leveraging its broader immunology portfolio, and potentially developing strategies for biosimilar market entry or defense.
Sources
[1] Papi, A., et al. (2016). Secukinumab vs. adalimumab for moderate-to-severe plaque psoriasis: the PURE study. British Journal of Dermatology, 175(4), 838-848.
[2] Langley, R. G., et al. (2014). Secukinumab in moderate-to-severe plaque psoriasis: results from the GALAXY 1 trial. British Journal of Dermatology, 170(2), 408-415.
[3] Mease, P. J., et al. (2017). Secukinumab treatment of psoriatic arthritis: A randomized controlled trial. Arthritis & Rheumatology, 69(11), 2116-2128.
[4] GlobalData Pharma Intelligence Center. (2023, October 26). Secukinumab (Cosentyx) Market Analysis, Forecast, and Competitive Landscape. (Report Data).
